Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04482686 · ClinicalTrials.gov registry record · Phase 1
Trial of Combination Therapy to Treat COVID-19 Infection
A Phase 1 study, sponsored by ProgenaBiome.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04482686 is a Phase 1 study that has completed, run by ProgenaBiome. The registered enrollment target is 31 participants.
The verdict
NCT04482686, a Phase 1 study, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
Interventions
- DRUG Ivermectin
- DIETARY_SUPPLEMENT Vitamin D3
- DIETARY_SUPPLEMENT Vitamin C
- DRUG Doxycycline Hcl
- DIETARY_SUPPLEMENT Zinc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04482686
The ClinicalTrials.gov registry entry for NCT04482686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProgenaBiome, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ivermectin is the first listed.
NCT04482686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04482686 about?
NCT04482686 is a clinical study titled "Trial of Combination Therapy to Treat COVID-19 Infection". In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
What is the current status of trial NCT04482686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2020-12-09. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT04482686?
The interventions under investigation include: Ivermectin (DRUG), Vitamin D3 (DIETARY_SUPPLEMENT), Vitamin C (DIETARY_SUPPLEMENT), Doxycycline Hcl (DRUG), Zinc (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04482686?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.